Skip to content
DataLookout
Menu

NCT07806045

Nebulized UC-EVs for Recurrent or Refractory IMIDs With Lung Involvement

StatusNot Yet Recruiting
PhaseEarly Phase 1
SponsorQiubai Li
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Incidence and Severity of Adverse Events and Serious Adverse Events
Timeframe: From first dose through Week 52
Maximum Tolerated Dose and Recommended Phase 2 Dose of Nebulized UC-EVs
Timeframe: Through the first 14-day treatment cycle for each dose cohort

Secondary (14)

Change From Baseline in Health Assessment Questionnaire Score
Change From Baseline in Patient Global Impression of Severity Score
Change From Baseline in St. George's Respiratory Questionnaire Score
Change From Baseline in Leicester Cough Questionnaire Score
Change From Baseline in Forced Vital Capacity at Week 24
Show 9 moreShow less
Percent Change From Baseline in Percent Predicted Diffusing Capacity of the Lung for Carbon Monoxide at Week 24
Change From Baseline in Maximum Pulmonary Nodule Size on Chest HRCT at Week 24
Change From Baseline in Bronchial Wall Thickness on Chest HRCT at Week 24
Change From Baseline in Quantitative Lung Fibrosis and Quantitative Ground-Glass Opacity Scores on Chest HRCT at Week 24
Change From Baseline in Quantitative Interstitial Lung Disease Score on Chest HRCT at Week 24
Change From Baseline in Disease-Related Serologic Markers (for IgG4-RD patients only)
Change From Baseline in Disease-Related Serologic Markers (for SSc patients only)
Change From Baseline in erythrocyte sedimentation rate
Change From Baseline in C-reactive protein

Arms and interventions

UC-EVs armExperimental

This open-label, dose-escalation study with up to three dose levels of nebulized UC-EVs. The maximum tolerated dose (MTD) of nebulized UC-EVs will be determined using dose-escalation 3+3 design. Dose Level 1: 5×10\^9 particles Dose Level 2: 1×10\^10 particles Dose Level 3: 2×10\^10 particles

Biologicals: nebulized human umbilical cord mesenchymal stromal cell-derived extracellular vesicles

Sites

1 site in 1 country

  • Peking Union Medical College HospitalBeijing, China